Literature DB >> 16150905

Differential biosynthesis and intracellular transport of follistatin isoforms and follistatin-like-3.

Seiichiro Saito1, Yisrael Sidis, Abir Mukherjee, Yin Xia, Alan Schneyer.   

Abstract

Follistatin (FST) and FST-like-3 (FSTL3) are structurally related proteins that bind and neutralize activin and closely related members of the TGFbeta superfamily. Three FST isoforms (FST288, FST303, and FST315) are produced from the Fst gene that are primarily secreted proteins. FSTL3 is secreted, but is also observed within the nucleus of most cells. We used pulse-chase (35)S labeling to examine the biosynthetic and intracellular transport patterns that lead to differential secretion and intracellular retention of these proteins. Among the FST isoforms, FST315 was secreted fastest and FST288 was secreted more slowly, with some remaining intracellular. In contrast, FSTL3 was secreted the slowest, with newly synthesized proteins being both secreted and trafficked to the nucleus. This nuclear FSTL3 was N-glycosylated, although not to the same degree as secreted FSTL3. Both FST and FSTL3 have two Mets in their signal sequence. Mutation of the first Met in FST288 eliminated protein translation, whereas FSTL3 could be translated from either Met. However, although FSTL3 translated from the second Met, which had no signal sequence, was confined to the nucleus, it was not glycosylated. Interestingly, this FSTL3 retained activin-antagonizing activity. Thus, although bioactive, nuclear FSTL3 can be translated from the second Met when the first Met is mutated, the glycosylated nuclear FSTL3 produced endogenously indicates that a different mechanism must be used under natural conditions that apparently includes N-glycosylation. Moreover, the differential biosynthetic and intracellular transport patterns for FST288 and FSTL3 suggest that these two activin-binding proteins may have distinct intracellular roles.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16150905     DOI: 10.1210/en.2005-0833

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  15 in total

1.  Molecular cloning and characterization of follistatin in the gilthead sea bream, Sparus aurata.

Authors:  Bruria Funkenstein; Yanai Rebhan; Tal Skopal
Journal:  Mol Biol Rep       Date:  2008-01-01       Impact factor: 2.316

2.  Follistatin-like 3 is a mediator of exercise-driven bone formation and strengthening.

Authors:  J Nam; P Perera; R Gordon; Y H Jeong; A D Blazek; D G Kim; B C Tee; Z Sun; T D Eubank; Y Zhao; B Lablebecioglu; S Liu; A Litsky; N L Weisleder; B S Lee; T Butterfield; A L Schneyer; S Agarwal
Journal:  Bone       Date:  2015-04-30       Impact factor: 4.398

3.  Activin-A and myostatin response and steroid regulation in human myometrium: disruption of their signalling in uterine fibroid.

Authors:  Pasquapina Ciarmela; Enrrico Bloise; Peter C Gray; Patrizia Carrarelli; Md Soriful Islam; Flavio De Pascalis; Filiberto Maria Severi; Wylie Vale; Mario Castellucci; Felice Petraglia
Journal:  J Clin Endocrinol Metab       Date:  2010-12-22       Impact factor: 5.958

4.  Nucleolar follistatin promotes cancer cell survival under glucose-deprived conditions through inhibiting cellular rRNA synthesis.

Authors:  Xiangwei Gao; Saisai Wei; Kairan Lai; Jinghao Sheng; Jinfeng Su; Junqiao Zhu; Haojie Dong; Hu Hu; Zhengping Xu
Journal:  J Biol Chem       Date:  2010-09-15       Impact factor: 5.157

5.  Evaluation of systemic follistatin as an adjuvant to stimulate muscle repair and improve motor function in Pompe mice.

Authors:  Joseph W Foley; Scott D Bercury; Patrick Finn; Seng H Cheng; Ronald K Scheule; Robin J Ziegler
Journal:  Mol Ther       Date:  2010-06-15       Impact factor: 11.454

Review 6.  The biology of activin: recent advances in structure, regulation and function.

Authors:  Yin Xia; Alan L Schneyer
Journal:  J Endocrinol       Date:  2009-03-09       Impact factor: 4.286

7.  The follistatin-288 isoform alone is sufficient for survival but not for normal fertility in mice.

Authors:  Fuminori Kimura; Yisrael Sidis; Lara Bonomi; Yin Xia; Alan Schneyer
Journal:  Endocrinology       Date:  2009-12-23       Impact factor: 4.736

8.  Growth differentiation factor 9 (GDF9) suppresses follistatin and follistatin-like 3 production in human granulosa-lutein cells.

Authors:  Feng-Tao Shi; Anthony P Cheung; He-Feng Huang; Peter C K Leung
Journal:  PLoS One       Date:  2011-08-01       Impact factor: 3.240

9.  Activin signaling as an emerging target for therapeutic interventions.

Authors:  Kunihiro Tsuchida; Masashi Nakatani; Keisuke Hitachi; Akiyoshi Uezumi; Yoshihide Sunada; Hiroshi Ageta; Kaoru Inokuchi
Journal:  Cell Commun Signal       Date:  2009-06-18       Impact factor: 5.712

10.  Differential expression of follistatin and FLRG in human breast proliferative disorders.

Authors:  Enrrico Bloise; Henrique L Couto; Lauretta Massai; Pasquapina Ciarmela; Marzia Mencarelli; Lavinia E Borges; Michela Muscettola; Giovanni Grasso; Vania F Amaral; Geovanni D Cassali; Felice Petraglia; Fernando M Reis
Journal:  BMC Cancer       Date:  2009-09-09       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.